Evidence map›Paper›PMID 26603890›Full record

ArticleThe AAPS journal2016

Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.

Wenbo Wang, Qi Tony Zhou, Si-Ping Sun, John A Denman, Thomas R Gengenbach, Nicolas Barraud, Scott A Rice, Jian Li, Mingshi Yang, Hak-Kim Chan

Open access · bronzeAbstract read
In one paragraph

Article in The AAPS journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Physical stability of dry powder inhaler formulations.Expert opinion on drug delivery · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 5 countries.

Wenbo WangDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark.
Qi Tony ZhouAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
Si-Ping SunAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
John A DenmanIan Wark Research Institute, University of South Australia, Mawson Lakes, South Australia, 5095, Australia.
Thomas R GengenbachCSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, 3168, Australia.
Nicolas BarraudCentre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.
Scott A RiceCentre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.
Jian LiDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Mingshi YangDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100, Copenhagen, Denmark. my@farma.ku.dk.
Hak-Kim ChanAdvanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.
University of Copenhagen · DKUniversity of Sydney · AUUNSW Sydney · AUCSIRO Manufacturing · AUMonash University · AUPurdue University West Lafayette · USUniversity of South Australia · AU

Funding

New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic CombinationsR01AI111965 · NIAID · MONASH UNIVERSITY · PI LI, JIAN · 2014 to 2018
$4.3M
Targeting superbugs: discovery and development of new broad-spectrum lipopeptidesR01AI098771 · NIAID · MONASH UNIVERSITY · PI LI, JIAN · 2012 to 2016
$4.3M
NIAID NIH HHS R01 AI098771NIAID NIH HHS R01 AI111965PHS HHS R01 A1098771
6 · The paper itself

Abstract

Colistin is often the only effective antibiotic against the respiratory infections caused by multidrug-resistant Gram-negative bacteria. However, colistin-resistant multidrug-resistant isolates have been increasingly reported and combination therapy is preferred to combat resistance. In this study, five combination formulations containing colistin (COL) and rifampicin (RIF) were prepared by spray drying. The lowest minimum inhibitory concentration (MIC) value against Pseudomonas aeruginosa PAO1 was measured for the formulation of COL/RIF = 4:1 with relatively high emitted doses (over 80%) and satisfactory fine particle fractions (over 60%). Data from X-ray photoelectron spectroscopy (XPS) and nano-time-of-flight secondary ion mass spectrometry (ToF-SIMS) showed the surfaces of particles were mainly covered by rifampicin even for the formulation with a mass ratio of COL/RIF = 4:1. Because colistin is hygroscopic and rifampicin is hydrophobic, moisture absorption of combination formulations was significantly lower than the pure colistin formulation in the dynamic vapour sorption results. To investigate the dissolution characteristics, four dissolution test methods (diffusion Franz cell, modified Franz cell, flow-through and beaker methods) were employed and compared. The modified Franz cell method was selected to test the dissolution behaviour of aerosolised powder formulations to eliminate the effect of membrane on dissolution. The results showed that surface enrichment of hydrophobic rifampicin neither affected aerosolisation nor retarded dissolution rate of colistin in the combination formulations. For the first time, advanced surface characterisation techniques of XPS and ToF-SIMS have shown their capability to understand the effect of surface composition on the aerosolisation and dissolution of combination powders.

Indexed as

Dry Powder InhalersAdministration, InhalationAerosolsAnti-Bacterial AgentsColistinMicrobial Sensitivity TestsParticle SizePseudomonas aeruginosaRespiratory Tract InfectionsRifampinSolubilitySurface PropertiesAerosolsAnti-Bacterial AgentsColistinRifampincolistincombination antibioticsdry powder inhalerrespiratory infectionrifampicin

Identifiers

PMID26603890
PMCPMC4779103
OpenAlexW2176838275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.